Cell-Based Assays Using IPSCS for Drug Development and Testing
Language: English
Published by Humana Pr Inc, 2025
- Hardcover
- New

Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
AbeBooks seller since January 6, 2003
Condition: New
US$ 285.83
Quantity: 1 available
Add to basketItem description from seller
Seller Inventory # zk1071645293
- Title
- Cell-Based Assays Using IPSCS for Drug Development and Testing
- Author
- Mandenius, Carl-fredrik (Editor)/ Ross, James A. (Editor)
- Publisher
- Humana Pr Inc
- Publication year
- 2025
- Condition
- Brand New
- Binding
- Hardcover
- Language
- English
- ISBN 10
- 1071645293
- ISBN 13
- 9781071645291
- Edition
- 2nd Edition
- Item weight
- 0.7 kilograms
This up-to-date volume presents a set of differentiation and assay protocols useful to researchers involved in disease modeling, drug discovery, and the cell biology of a variety of tissues. The book begins with chapters on culture of induced pluripotent stem cells (iPSCs) and iPSC-derived cells with detailed protocols for culturing and differentiation of iPSC-derived endoderm, hepatocytes, vascular endothelial cells, cardiomyocytes, renal podocytes, neurons, and astrocytes. This is accompanied by newer protocols for the use of 3D cultures in assays adapted for drug development purposes, with new techniques such as high content analysis and microphysiological systems. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step and readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Authoritative and practical, Cell-Based Assays Using iPSCs for Drug Development and Testing, Second Edition serves as an ideal guide for scientists working to develop human iPSC-derived cellular models for drug discovery, efficacy, and safety purposes.
"Synopsis" may belong to another edition of this title.
From the Back Cover
This up-to-date volume presents a set of differentiation and assay protocols useful to researchers involved in disease modeling, drug discovery, and the cell biology of a variety of tissues. The book begins with chapters on culture of induced pluripotent stem cells (iPSCs) and iPSC-derived cells with detailed protocols for culturing and differentiation of iPSC-derived endoderm, hepatocytes, vascular endothelial cells, cardiomyocytes, renal podocytes, neurons, and astrocytes. This is accompanied by newer protocols for the use of 3D cultures in assays adapted for drug development purposes, with new techniques such as high content analysis and microphysiological systems. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step and readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Authoritative and practical, Cell-Based Assays Using iPSCs for Drug Development and Testing, Second Edition serves as an ideal guide for scientists working to develop human iPSC-derived cellular models for drug discovery, efficacy, and safety purposes.
"About the title" may belong to another edition of this title.
Revaluation Books
Exeter, United Kingdom
AbeBooks seller since January 6, 2003
Shipping rates from United Kingdom to U.S.A.
| Item | 7 to 14 business days | 2 to 3 business days |
|---|---|---|
| First item | US$ 16.90 | US$ 33.79 |
Payment methods
Seller's business information
Edward Bowditch Ltd
Exstowe, Exton
Exeter, United Kingdom EX3 0PP
Terms of sale
Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch
Shipping terms
Orders usually dispatched within two working days. Please note that at this time all domestic United Kingdom orders are sent by trackable UPS courier, we choose not to offer a lower cost alternative.